[go: up one dir, main page]

AT514533A3 - Krebsmedikament - Google Patents

Krebsmedikament Download PDF

Info

Publication number
AT514533A3
AT514533A3 ATA50431/2014A AT504312014A AT514533A3 AT 514533 A3 AT514533 A3 AT 514533A3 AT 504312014 A AT504312014 A AT 504312014A AT 514533 A3 AT514533 A3 AT 514533A3
Authority
AT
Austria
Prior art keywords
cancer drug
cancer cell
cancer
drug
furfural
Prior art date
Application number
ATA50431/2014A
Other languages
English (en)
Other versions
AT514533A2 (de
AT514533B1 (de
Inventor
Christoph Dr Pallua
Original Assignee
Christoph Dr Pallua
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christoph Dr Pallua filed Critical Christoph Dr Pallua
Publication of AT514533A2 publication Critical patent/AT514533A2/de
Publication of AT514533A3 publication Critical patent/AT514533A3/de
Application granted granted Critical
Publication of AT514533B1 publication Critical patent/AT514533B1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Ein Krebsmedikament wird durch Synthese eines für die Krebszelle toxischen Stoffs, beispielsweise Furfural, und eines durch den Gärungsstoffwechsel der Krebszelle metabolisierbaren Stoff, beispielsweise Gluconsäure, gebildet.
ATA50431/2014A 2013-06-21 2014-06-20 Krebsmedikament AT514533B1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE201310106530 DE102013106530A1 (de) 2013-06-21 2013-06-21 Krebsmedikament

Publications (3)

Publication Number Publication Date
AT514533A2 AT514533A2 (de) 2015-01-15
AT514533A3 true AT514533A3 (de) 2016-06-15
AT514533B1 AT514533B1 (de) 2017-04-15

Family

ID=52010284

Family Applications (1)

Application Number Title Priority Date Filing Date
ATA50431/2014A AT514533B1 (de) 2013-06-21 2014-06-20 Krebsmedikament

Country Status (3)

Country Link
AT (1) AT514533B1 (de)
CH (1) CH708261A2 (de)
DE (1) DE102013106530A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016113143A1 (de) 2016-07-15 2018-01-18 Christoph Pallua Krebsmedikament

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1834951A1 (de) * 2006-03-10 2007-09-19 Avantium International B.V. Verfahren zur Herstellung von organischen 5-Hydroxymethylfurfuralsäureestern und ihre Verwendung
EP1958944A1 (de) * 2007-02-16 2008-08-20 Evonik Degussa GmbH Verfahren zur Herstellung von 5-Hydroxymethyl-furfural über 5-Acyloxymethyl-furfural als Zwischenprodukt
WO2009030512A2 (en) * 2007-09-07 2009-03-12 Furanix Technologies B.V. Hydroxymethylfurfural ethers and esters prepared in ionic liquids
US20090156841A1 (en) * 2007-12-12 2009-06-18 Sanborn Alexandra J Conversion of carbohydrates to hydroxymethylfurfural (hmf) and derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT393221B (de) * 1988-02-03 1991-09-10 Leopold Pharma Gmbh Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken
AT412447B (de) * 2002-11-27 2005-03-25 C Y L Handelsges M B H Mittel mit zerstörender wirkung auf maligne tumore sowie verfahren zu seiner herstellung
US20050124684A1 (en) * 2003-08-29 2005-06-09 Ying Du 5-(hydroxymethyl) furfural and derivatives as inhibitors of TNFalpha and IL-1beta production
JP4693093B2 (ja) * 2005-01-27 2011-06-01 国立大学法人 鹿児島大学 抗癌剤
KR101377037B1 (ko) * 2010-11-11 2014-03-21 주식회사 노암 항암용 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1834951A1 (de) * 2006-03-10 2007-09-19 Avantium International B.V. Verfahren zur Herstellung von organischen 5-Hydroxymethylfurfuralsäureestern und ihre Verwendung
EP1958944A1 (de) * 2007-02-16 2008-08-20 Evonik Degussa GmbH Verfahren zur Herstellung von 5-Hydroxymethyl-furfural über 5-Acyloxymethyl-furfural als Zwischenprodukt
WO2009030512A2 (en) * 2007-09-07 2009-03-12 Furanix Technologies B.V. Hydroxymethylfurfural ethers and esters prepared in ionic liquids
US20090156841A1 (en) * 2007-12-12 2009-06-18 Sanborn Alexandra J Conversion of carbohydrates to hydroxymethylfurfural (hmf) and derivatives

Also Published As

Publication number Publication date
AT514533A2 (de) 2015-01-15
DE102013106530A1 (de) 2014-12-24
AT514533B1 (de) 2017-04-15
CH708261A2 (de) 2014-12-31

Similar Documents

Publication Publication Date Title
EA201400753A1 (ru) Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их
PH12018501094A1 (en) Process for the preparation of an apoptosis-inducing agent
ECSP20021132A (es) Enantiómeros de tiazoles sustituidos compuestos antivirales
MX2015017870A (es) Procedimiento para producir 4-propargilado amino-benzoxazinonas.
BR112016010573A8 (pt) composições de fertilizantes
TR201902709T4 (tr) Mek inhibitörleri olarak bileşikler ve bileşimler.
BR112017020690A2 (pt) produção livre de células de ácido ribonucleico
WO2015161468A8 (en) Methods and systems for producing isosorbide from biomass
MX373335B (es) Producción de piripiropenos a partir de biomasa seca.
MY183026A (en) Method for producing conjugated diene
WO2014210416A8 (en) Helicase suppression of non-template amplification
EP3124604A3 (de) Säuretolerante hefezelle, verfahren zur herstellung von organischer säure unter verwendung davon und verfahren zur herstellung der hefezelle
SA518392272B1 (ar) منتج شبه مكتمل، طريقة إنتاجه واستخدامه
MX2016005223A (es) Tinturas dispersas, su preparacion y su uso.
AT514533A3 (de) Krebsmedikament
MX2016007340A (es) Formulacion de biomasa.
MX2015016603A (es) Composiciones de corticosteroides.
CR20150387A (es) Proceso para producir compuesto de piridazinona y producción de sus intermediarios
CU20150015A7 (es) Tris-(hetero)aril-pirazoles y su uso
ECSP15040447A (es) Método de producción de compuestos de piridazinona
MY175821A (en) Microorganism having ability to produce o-succinylhomoserine or succinic acid, and method for producing succinic acid or o-succinylhomoserine by using same
MX2015017198A (es) Matriz.
BR112015029599A2 (pt) tinturas ácidas, processo para a produção das mesmas e seu uso
BR112017016626A2 (pt) micro-organismo com capacidade para produzir ácido quinólico e método para produzir ácido quinólico com o uso do micro-organismo
MX2016005220A (es) Tinturas acidas, proceso para su produccion y su uso.

Legal Events

Date Code Title Description
MM01 Lapse because of not paying annual fees

Effective date: 20200620